Medpace CEO August Troendle sells $1.59 million in stock

August J. Troendle, President and CEO of Medpace Holdings, Inc. (NASDAQ:MEDP), recently sold common stock totaling approximately $1.59 million, according to a filing with the U.S. Securities and Exchange Commission. The transactions occurred on September 25 and September 28, 2026, with shares sold at prices ranging from $620.07 to $620.6. The stock has since climbed to $669.20, trading near its 52-week high of $684.52, according to InvestingPro data. The platform currently identifies the stock as overvalued relative to its Fair Value estimate.

On September 25, Mr. Troendle disposed of 154 shares of Medpace Holdings common stock at a price of $620.6 per share. A subsequent transaction on September 28 involved the sale of 2,410 shares at a weighted average price of $620.07. These individual sales ranged from $620.00 to $621.20. These sales were executed pursuant to a limit order placed by Mr. Troendle during an open window period.

Following these transactions, Mr. Troendle directly holds 386,892 shares of Medpace Holdings common stock. Additionally, he indirectly beneficially owns 4,733,019 shares through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder. Mr. Troendle disclaims beneficial ownership of these indirectly held securities except to the extent of his pecuniary interest.

In other recent news, Medpace Holdings reported robust financial results for the third quarter of 2026. The company exceeded Wall Street expectations with an adjusted profit of $4.84 per share, surpassing the forecasted $4.44. Revenue for the quarter reached $716 million, slightly above the anticipated $714.47 million, marking an 8.5% increase from the previous year. Net income rose by 23.7%, and the EBITDA margin expanded to 24.0%, up from 22.5% a year earlier, driven by lower reimbursable costs. Additionally, Medpace achieved record-high net new business awards, which bolstered its backlog. Management has raised its full-year 2026 revenue and profit guidance, although they have postponed 2027 guidance until February due to uncertainties regarding awards and cancellations. The company highlighted strong demand in its oncology segment, despite a slight decline in cardiometabolic demand. These developments underscore a positive business environment, characterized by high-quality request-for-proposal activity and faster customer decision times.